Compare OFIX & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFIX | RGNX |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.3M | 528.6M |
| IPO Year | 1998 | 2015 |
| Metric | OFIX | RGNX |
|---|---|---|
| Price | $9.33 | $6.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $17.25 | ★ $28.75 |
| AVG Volume (30 Days) | 445.0K | ★ 1.9M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.39 | 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $822,312,000.00 | $10,393,000.00 |
| Revenue This Year | $6.13 | $51.21 |
| Revenue Next Year | $6.22 | $19.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.85 | ★ 126.48 |
| 52 Week Low | $9.13 | $5.46 |
| 52 Week High | $16.99 | $16.19 |
| Indicator | OFIX | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 27.27 | 42.45 |
| Support Level | N/A | $5.46 |
| Resistance Level | $12.72 | $10.13 |
| Average True Range (ATR) | 0.63 | 0.66 |
| MACD | -0.30 | -0.06 |
| Stochastic Oscillator | 4.06 | 25.57 |
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.